99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: immune therapies of type 1 diabetes: new opportunities based on the hygiene hypothesis.
Insulin-dependent (type 1) diabetes is a prototypic organ-specific autoimmune disease resulting from the selective destruction of insulin-secreting beta cells within pancreatic islets of Langerhans by an immune-mediated inflammation involving autoreactive CD4(+) and CD8(+) T lymphocytes which infiltrate pancreatic islets. Current treatment is substitutive, i.e. chronic use of exogenous insulin which, in spite of significant advances, is still associated with major constraints (multiple daily injections, risks of hypoglycaemia) and lack of effectiveness over the long term in preventing severe degenerative complications. Finding a cure for autoimmune diabetes by establishing effective immune-based therapies is a real medical health challenge, as the disease incidence increases steadily in industrialized countries. As the disease affects mainly children and young adults, any candidate immune therapy must therefore be safe and avoid a sustained depression of immune responses with the attendant problems of recurrent infection and drug toxicity. Thus, inducing or restoring immune tolerance to target autoantigens, controlling the pathogenic response while preserving the host reactivity to exogenous/unrelated antigens, appears to be the ideal approach. Our objective is to review the major progress accomplished over the last 20 years towards that aim. In addition, we would like to present another interesting possibility to access new preventive strategies based on the 'hygiene hypothesis', which proposes a causal link between the increasing incidence of autoimmune diseases, including diabetes, and the decrease of the infectious burden. The underlying rationale is to identify microbial-derived compounds mediating the protective activity of infections which could be developed therapeutically.
Chatenoud
L
L
Université Paris Descarte, Paris, France. lucienne.chatenoud@inserm.fr
You
S
S
Okada
H
H
Kuhn
C
C
Michaud
B
B
Bach
J-F
JF
D000293:Adolescent; D000818:Animals; D001324:Autoantigens / Q000276:immunology; D001419:Bacteria / Q000276:immunology; D002170:Canada / Q000453:epidemiology; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000628:therapy*; D005060:Europe / Q000453:epidemiology; D006801:Humans; D006920:Hygiene; D006967:Hypersensitivity / Q000276:immunology; D007165:Immunosuppression Therapy / Q000379:methods; D007167:Immunotherapy / Q000379:methods*; D007239:Infections / Q000276:immunology / Q000382:microbiology; D051379:Mice; D010195:Pancreatitis / Q000276:immunology / Q000382:microbiology; D051193:Toll-Like Receptors / Q000819:agonists; D055815:Young Adult
D001324:Autoantigens; D051193:Toll-Like Receptors